# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

> **NCT01702467** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 27 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** GSK2647544
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01702467
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-19
- **Primary completion:** 2013-05-15
- **Final completion:** 2013-05-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702467, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01702467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*